Ustekinumab Real World Evidence Study

University Hospital Southampton NHS Foundation Trust601 enrolled

Overview

The purpose of this study is to capture the real-world experience of CD patients treated with ustekinumab as part of their clinical care in a variety of care settings from large teaching/research centres to smaller district hospitals. It will utilise existing research networks to deliver the study effectively. The UK IBD community has strongly demonstrated that it is both willing and able to work on collaborative projects, ranging from interventional trials (TOPPIC, CONSTRUCT) and prospective observational studies (PANTS, VEST), through to case finding studies (PRED4) as well as retrospective cohort studies (UK experience of withdrawal of thiopurines \[PMID 25284134\] and anti-TNF\[PMID 26892328\]) as well as the UK IBD BioResource. PANTS successfully recruited from 120 sites in the UK. The study will in part use the UK IBD Registry infrastructure to leverage the impact of the data. These collaborations have led to significant publications in high impact journals, and will impact directly on the management of IBD patients in the near future. Key to this successful work is the National Institute of Health Research (NIHR), which supports local Clinical Research Networks in the delivery of multicentre research.

Study Type

OBSERVATIONAL

Enrollment

601

Conditions

Crohn's Disease

Interventions

UstekinumabDRUG

Intravenous baseline, subcutaneous follow ups.

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Participants being given ustekinumab as part of their routine clinical care * Any of the following clinical indications: * CRP of 5mg/L or higher within three months prior to baseline * Faecal calprotectin of 250mg/L or higher within three months prior to baseline * Active disease on endoscopy within 6 months prior to baseline * Switching to ustekinumab because of an AE on another treatment * Post-operative prophylaxis * Age 18 or over * Able to give informed consent * Able to read English Exclusion Criteria: * Patient is, in the opinion of the investigator, not suitable to participate in the study * Use of ustekinumab outside of UK SmPC * Currently enrolled in an IMP/interventional study * Has received ustekinumab previously

Locations (22)

University Hospitals Bristol NHS Foundation Trust

Outcomes

Primary Outcomes

Steroid-free remission

Steroid-free remission at one year as defined by a mHBI at week 56 of less than or equal to 4.

Time frame: One year

Secondary Outcomes

Description of the demographics, disease phenotype, disease history, treatment history and concomitant medication use of patients receiving ustekinumab.

Collected from medical records and patient

Time frame: Two years

Remission and response rates

Response to treatment as measured by modified Harvey Bradshaw Index (mHBI)

Time frame: Week 8, Week 14/16, Week 56, Week 82, Week 108 or until treatment stopped

Remission and response rates

Response to treatment as measured by Physician's Global Assessment (PGA)

Time frame: Week 8, Week 14/16, Week 56, Week 82, Week 108 or until treatment stopped

Remission and response rates

Response to treatment as measured by IBD Control PROM (Patient Reported Outcome Measures)

Time frame: Week 8, Week 14/16, Week 56, Week 82, Week 108 or until treatment stopped

Drug persistence

Enquiring of the patient whether they are still administering the treatment at each follow up visit

Time frame: Week 8, Week 14/16, Week 56, Week 82, Week 108 or until treatment stopped

Patient experience of ustekinumab as assessed by Treatment Satisfaction Questionnaire for Medication (TSQM)

Multiple choice questionnaire about patient's experience of using the medication

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.